|
1
|
Li P, Znaor A, Holcatova I, Fabianova E,
Mates D, Wozniak MB, Ferlay J and Scelo G: Regional geographic
variations in kidney cancer incidence rates in European countries.
Eur Urol. 67:1134–1141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Srinivasan R, Ricketts CJ, Sourbier C and
Linehan WM: New strategies in renal cell carcinoma: Targeting the
genetic and metabolic basis of disease. Clin Cancer Res. 21:10–17.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Capitanio U and Montorsi F: Renal cancer.
Lancet. 387:894–906. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gossage L and Eisen T: Alterations in VHL
as potential biomarkers in renal-cell carcinoma. Nat Rev Clin
Oncol. 7:277–288. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cancer Genome Atlas Research Network:
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ibragimova I, Maradeo ME, Dulaimi E and
Cairns P: Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2,
KDM6A and other chromatin-modifying genes is absent or rare in
clear cell RCC. Epigenetics. 8:486–493. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Valera VA, Walter BA, Linehan WM and
Merino MJ: Regulatory effects of microRNA-92 (miR-92) on VHL gene
expression and the hypoxic activation of miR-210 in clear cell
renal cell carcinoma. J Cancer. 2:515–526. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McCormick RI, Blick C, Ragoussis J,
Schoedel J, Mole DR, Young AC, Selby PJ, Banks RE and Harris AL:
miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal
cancer, regulates ISCU and correlates with good prognosis. Br J
Cancer. 108:1133–1142. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peña-Llopis S, Vega-Rubín-de-Celis S, Liao
A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L,
Sivanand S, Spence P, et al: BAP1 loss defines a new class of renal
cell carcinoma. Nat Genet. 44:751–759. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eckel-Passow JE, Serie DJ, Bot BM, Joseph
RW, Cheville JC and Parker AS: ANKS1B is a smoking-related
molecular alteration in clear cell renal cell carcinoma. BMC Urol.
14:142014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takahashi M, Tsukamoto Y, Kai T, Tokunaga
A, Nakada C, Hijiya N, Uchida T, Daa T, Nomura T, Sato F, et al:
Downregulation of WDR20 due to loss of 14q is involved in the
malignant transformation of clear cell renal cell carcinoma. Cancer
Sci. 107:417–423. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41:(Database Issue):.
D991–D995. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang da W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: Paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45:D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bader GD and Hogue CW: An automated method
for finding molecular complexes in large protein interaction
networks. BMC Bioinformatics. 4:22003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang J, Duncan D, Shi Z and Zhang B:
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): Update 2013.
Nucleic Acids Res. 41:W77–W83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schödel J, Grampp S, Maher ER, Moch H,
Ratcliffe PJ, Russo P and Mole DR: Hypoxia, hypoxia-inducible
transcription factors, and renal cancer. Eur Urol. 69:646–657.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Escudier B, Szczylik C, Porta C and Gore
M: Treatment selection in metastatic renal cell carcinoma: Expert
consensus. Nat Rev Clin Oncol. 9:327–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ciccarese C, Brunelli M, Montironi R,
Fiorentino M, Iacovelli R, Heng D, Tortora G and Massari F: The
prospect of precision therapy for renal cell carcinoma. Cancer
Treat Rev. 49:37–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu C, Wang Y, Cai C and Cai Q: Bacterial
infection and associated cancers. Adv Exp Med Biol. 1018:181–191.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hattar K, Reinert CP, Sibelius U,
Gökyildirim MY, Subtil FSB, Wilhelm J, Eul B, Dahlem G, Grimminger
F, Seeger W and Grandel U: Lipoteichoic acids from Staphylococcus
aureus stimulate proliferation of human non-small-cell lung cancer
cells in vitro. Cancer Immunol Immunother. 66:799–809. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fizazi K, Cojean I, Pignon JP, Rixe O,
Gatineau M, Hadef S, Arriagada R, Baldeyrou P, Comoy E and Le
Chevalier T: Normal serum neuron specific enolase (NSE) value after
the first cycle of chemotherapy: An early predictor of complete
response and survival in patients with small cell lung carcinoma.
Cancer. 82:1049–1055. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oremek GM, Sauer-Eppel H and Bruzdziak TH:
Value of tumour and inflammatory markers in lung cancer. Anticancer
Res. 27:1911–1915. 2007.PubMed/NCBI
|
|
27
|
Zhang T, Niu X, Liao L, Cho EA and Yang H:
The contributions of HIF-target genes to tumor growth in RCC. PLoS
One. 8:e805442013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
MacLachlan TK, Sang N and Giordano A:
Cyclins, cyclin-dependent kinases and cdk inhibitors: Implications
in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr.
5:127–156. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alao JP: The regulation of cyclin D1
degradation: Roles in cancer development and the potential for
therapeutic invention. Mol Cancer. 6:242007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Arber N, Hibshoosh H, Moss SF, Sutter T,
Zhang Y, Begg M, Wang S, Weinstein IB and Holt PR: Increased
expression of cyclin D1 is an early event in multistage colorectal
carcinogenesis. Gastroenterology. 110:669–674. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gautschi O, Ratschiller D, Gugger M,
Betticher DC and Heighway J: Cyclin D1 in non-small cell lung
cancer: a key driver of malignant transformation. Lung Cancer.
55:1–14. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bosch F, Jares P, Campo E, Lopez-Guillermo
A, Piris MA, Villamor N, Tassies D, Jaffe ES, Montserrat E, Rozman
C, et al: PRAD-1/cyclin D1 gene overexpression in chronic
lymphoproliferative disorders: A highly specific marker of mantle
cell lymphoma. Blood. 84:2726–2732. 1994.PubMed/NCBI
|
|
33
|
Faust JB and Meeker TC: Amplification and
expression of the bcl-1 gene in human solid tumor cell lines.
Cancer Res. 52:2460–2463. 1992.PubMed/NCBI
|
|
34
|
Buckley MF, Sweeney KJ, Hamilton JA, Sini
RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA and
Sutherland RL: Expression and amplification of cyclin genes in
human breast cancer. Oncogene. 8:2127–2133. 1993.PubMed/NCBI
|
|
35
|
Han EK, Sgambato A, Jiang W, Zhang YJ,
Santella RM, Doki Y, Cacace AM, Schieren I and Weinstein IB: Stable
overexpression of cyclin D1 in a human mammary epithelial cell line
prolongs the S-phase and inhibits growth. Oncogene. 10:953–961.
1995.PubMed/NCBI
|
|
36
|
Han EK, Begemann M, Sgambato A, Soh JW,
Doki Y, Xing WQ, Liu W and Weinstein IB: Increased expression of
cyclin D1 in a murine mammary epithelial cell line induces p27kip1,
inhibits growth, and enhances apoptosis. Cell Growth Differ.
7:699–710. 1996.PubMed/NCBI
|
|
37
|
Sofer-Levi Y and Resnitzky D: Apoptosis
induced by ectopic expression of cyclin D1 but not cyclin E.
Oncogene. 13:2431–2437. 1996.PubMed/NCBI
|
|
38
|
Kotelnikov VM, Coon JS IV, Mundle S,
Kelanic S, LaFollette S, Taylor S IV, Hutchinson J, Panje W,
Caldarelli DD and Preisler HD: Cyclin D1 expression in squamous
cell carcinomas of the head and neck and in oral mucosa in relation
to proliferation and apoptosis. Clin Cancer Res. 3:95–101.
1997.PubMed/NCBI
|
|
39
|
Tang SW, Chang WH, Su YC, Chen YC, Lai YH,
Wu PT, Hsu CI, Lin WC, Lai MK and Lin JY: MYC pathway is activated
in clear cell renal cell carcinoma and essential for proliferation
of clear cell renal cell carcinoma cells. Cancer Lett. 273:35–43.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sgambato A, Migaldi M, Faraglia B, de
Aloysio G, Ferrari P, Ardito R, de Gaetani C, Capelli G, Cittadini
A and Trentini GP: Cyclin D1 expression in papillary superficial
bladder cancer: Its association with other cell cycle-associated
proteins, cell proliferation and clinical outcome. Int J Cancer.
97:671–678. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Holland TA, Elder J, McCloud JM, Hall C,
Deakin M, Fryer AA, Elder JB and Hoban PR: Subcellular localisation
of cyclin D1 protein in colorectal tumours is associated with
p21(WAF1/CIP1) expression and correlates with patient survival. Int
J Cancer. 95:302–306. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ogino S, Nosho K, Irahara N, Kure S, Shima
K, Baba Y, Toyoda S, Chen L, Giovannucci EL, Meyerhardt JA and
Fuchs CS: A cohort study of cyclin D1 expression and prognosis in
602 colon cancer cases. Clin Cancer Res. 15:4431–4438. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland
F, et al: Sorafenib for treatment of renal cell carcinoma: Final
efficacy and safety results of the phase III treatment approaches
in renal cancer global evaluation trial. J Clin Oncol.
27:3312–3318. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Klatte T, Seligson DB, LaRochelle J, Shuch
B, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Pantuck AJ and
Belldegrun AS: Molecular signatures of localized clear cell renal
cell carcinoma to predict disease-free survival after nephrectomy.
Cancer Epidemiol Biomarkers Prev. 18:894–900. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Beuselinck B, Jean-Baptiste J, Schöffski
P, Couchy G, Meiller C, Rolland F, Allory Y, Joniau S, Verkarre V,
Elaidi R, et al: Validation of VEGFR1 rs9582036 as predictive
biomarker in metastatic clear-cell renal cell carcinoma patients
treated with sunitinib. BJU Int. 118:890–901. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kendall RL and Thomas KA: Inhibition of
vascular endothelial cell growth factor activity by an endogenously
encoded soluble receptor. Proc Natl Acad Sci USA. 90:10705–10709.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Miyake T, Kumasawa K, Sato N, Takiuchi T,
Nakamura H and Kimura T: Soluble VEGF receptor 1 (sFLT1) induces
non-apoptotic death in ovarian and colorectal cancer cells. Sci
Rep. 6:248532016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Takano S, Ishikawa E, Matsuda M, Sakamoto
N, Akutsu H, Yamamoto T and Matsumura A: The anti-angiogenic role
of soluble-form VEGF receptor in malignant gliomas. Int J Oncol.
50:515–524. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Niu J, Wang Y, Wang J, Bin L and Hu X:
Delivery of sFIT-1 engineered MSCs in combination with a continuous
low-dose doxorubicin treatment prevents growth of liver cancer.
Aging (Albany NY). 8:3520–3534. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Vilsmaier T, Rack B, Janni W, Jeschke U
and Weissenbacher T; SUCCESS Study Group: Angiogenic cytokines and
their influence on circulating tumour cells in sera of patients
with the primary diagnosis of breast cancer before treatment. BMC
Cancer. 16:5472016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kwaan HC and McMahon B: The role of
plasminogen-plasmin system in cancer. Cancer Treat Res. 148:43–66.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
McMahon BJ and Kwaan HC: Components of the
plasminogen-plasmin system as biologic markers for cancer. Adv Exp
Med Biol. 867:145–156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Schrödter S, Braun M, Syring I, Klümper N,
Deng M, Schmidt D, Perner S, Müller SC and Ellinger J:
Identification of the dopamine transporter SLC6A3 as a biomarker
for patients with renal cell carcinoma. Mol Cancer. 15:102016.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhao S, Dorn J, Napieralski R, Walch A,
Diersch S, Kotzsch M, Ahmed N, Hooper JD, Kiechle M, Schmitt M and
Magdolen V: Plasmin(ogen) serves as a favorable biomarker for
prediction of survival in advanced high-grade serous ovarian
cancer. Biol Chem. 398:765–773. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mojiri A, Stoletov K, Carrillo MA,
Willetts L, Jain S, Godbout R, Jurasz P, Sergi CM, Eisenstat DD,
Lewis JD and Jahroudi N: Functional assessment of von Willebrand
factor expression by cancer cells of non-endothelial origin.
Oncotarget. 8:13015–13029. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mochizuki S, Soejima K, Shimoda M, Abe H,
Sasaki A, Okano HJ, Okano H and Okada Y: Effect of ADAM28 on
carcinoma cell metastasis by cleavage of von Willebrand factor. J
Natl Cancer Inst. 104:906–922. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Braybrooke JP, O'Byrne KJ, Propper DJ,
Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew
J, et al: A phase II study of razoxane, an antiangiogenic
topoisomerase II inhibitor, in renal cell cancer with assessment of
potential surrogate markers of angiogenesis. Clin Cancer Res.
6:4697–4704. 2000.PubMed/NCBI
|
